Beyond Air (XAIR) Q2 Earnings call transcript Nov 11, 2025
1min read In Beyond Air's Q2 earnings call for fiscal year 2025, executives discussed the company's operational highlights and financial results, providing insights into the company's commercial strategy and future prospects. The call, led by Steven Lisi, Chairman and Executive Officer, and Douglas Larson, Chief Financial Officer, highlighted several key themes and trends that demonstrate Beyond Air's progress and strategic positioning in the healthcare industry.
Commercial Success and Strategic Partnerships
Beyond Air reported a significant increase in hospital client contracts by over 60%, signaling a positive response to recent marketing and customer education initiatives. This momentum is expected to continue, with new contracts anticipated in the coming quarters. The company's strategic partnerships, including those with Healthcare Links, TrillaMed, and Asian business consultants, are expected to expand Beyond Air's reach into new markets, particularly in the European, South American, Asia Pacific, and Gulf Coast regions.
Financial Outlook and Cash Runway
Beyond Air's financial agreements, including a private placement equity offering, extinguishment of a senior secured term loan, and a royalty funding agreement, are expected to extend the company's cash runway for approximately 18 months. This financial stability will support the company's global commercial execution plan, particularly in light of regulatory and product development milestones on the horizon.
Regulatory and Product Development Milestones
The company's regulatory milestones include the pending PMA supplement for the expansion of the LungFit PH label to include cardiac surgery, which, if granted, would be the first formal FDA approval for nitric oxide products in this application. Beyond Air also anticipates filing a PMA supplement for the next-generation LungFit PH system in the first quarter of fiscal year 2026. These regulatory achievements, coupled with the company's strategic partnerships and product innovations, position Beyond Air for continued growth and market differentiation.
Looking Ahead
Beyond Air's Q2 earnings call underscores the company's commercial success and strategic positioning in the healthcare industry. The company's focus on expanding its customer base, strategic partnerships, and regulatory milestones set the stage for continued growth and market differentiation. With a robust financial outlook and a strong commitment to innovation, Beyond Air is well-positioned to capitalize on the opportunities in the nitric oxide market and beyond.